Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 14 · below the Ichimoku cloud · RSI 33 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.1M | 0.00% | 192.99K | +86% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a COYA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -19.8 | 6.7 | -20.6 | 7.4 | 13.9 | 21.4 | -28.4 | 8.8 | 9.9 | -16.6 | −27.9% | ||
| 2025 | 6.1 | 16.4 | -8.6 | 1.9 | -19.1 | 7.9 | 3.5 | 10.3 | -13.1 | 10.9 | 3.0 | -10.9 | +1.2% |
| 2024 | -20.4 | 52.4 | 10.3 | -8.8 | -15.8 | -20.5 | 13.2 | -12.1 | 7.0 | 12.1 | -9.8 | -12.1 | −22.7% |
| 2023 | -10.2 | -3.9 | -2.8 | 21.3 | -7.3 | -8.9 | -2.2 | -11.3 | 8.8 | 22.9 | 12.9 | 39.0 | +56.4% |
| 2022 | — |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 17, 2025 | Goldstein Dov ADirector | Conversion of Exercise of derivative security at price 1.09 per share. | 17.6K | $19.14K |
| Nov 13, 2024 | Snyder David S.Chief Financial Officer | Purchase at price 7.19 per share. | 1.8K | $12.93K |
| Nov 12, 2024 | Swaminathan Arun Ph.D.Chief Executive Officer | Purchase at price 7.36 per share. | 5K | $36.80K |
| Nov 10, 2024 | Grossman FredOfficer | Purchase at price 7.37 per share. | 2.7K | $19.97K |
| Nov 10, 2024 | Swaminathan Arun Ph.D.Chief Executive Officer | Purchase at price 7.34 per share. | 5K | $36.69K |
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Buy / hold / sell counts